CancerDrs

Cervical Cancer clinical trials in Florida

60 actively recruiting cervical cancer trials at 36 sites across Florida.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 2 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll.

Phase 3 Recruiting NIH

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

This phase III trial compares the addition of induction chemotherapy, with carboplatin, paclitaxel and pembrolizumab, to chemotherapy and radiation, with cisplatin and pembrolizumab followed by pembrolizumab maintenance for the treatment o…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07061977
Sites in Florida:
  • UM Sylvester Comprehensive Cancer Center at Coral Gables — Coral Gables, Florida
  • UM Sylvester Comprehensive Cancer Center at Coral Springs — Coral Springs, Florida
  • UM Sylvester Comprehensive Cancer Center at Deerfield Beach — Deerfield Beach, Florida
  • UM Sylvester Comprehensive Cancer Center at Doral — Doral, Florida
  • Broward Health Medical Center — Fort Lauderdale, Florida
Phase 2, Phase 3 Recruiting Academic/Other

Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer

This phase II/III trial studies how well sentinel lymph node biopsy works and compares sentinel lymph node biopsy surgery to standard neck dissection as part of the treatment for early-stage oral cavity cancer. Sentinel lymph node biopsy s…

Sponsor: NRG Oncology
NCT ID: NCT04333537
Sites in Florida:
  • UM Sylvester Comprehensive Cancer Center at Coral Gables — Coral Gables, Florida
  • UM Sylvester Comprehensive Cancer Center at Deerfield Beach — Deerfield Beach, Florida
  • University of Miami Miller School of Medicine-Sylvester Cancer Center — Miami, Florida
Phase 3 Recruiting Industry

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth factor recept…

Sponsor: AstraZeneca
NCT ID: NCT07431281
Sites in Florida:
  • Research Site — Fort Myers, Florida
  • Research Site — Jacksonville, Florida
  • Research Site — Jacksonville, Florida
  • Research Site — Orlando, Florida
  • Research Site — St. Petersburg, Florida
Phase 3 Recruiting Industry

A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma

The goal of this study is to understand whether CRB-701, a targeted form of chemotherapy called an anti-body drug conjugate, will work as a treatment for oropharyngeal (throat, tonsil) cancer. In patients who have already received platinum…

Sponsor: Corbus Pharmaceuticals Inc.
NCT ID: NCT07768189
Sites in Florida:
  • Florida Cancer Specialists and Research Institute — Orlando, Florida
  • Moffitt Cancer Center Magnolia Campus — Tampa, Florida
Phase 3 Recruiting Industry

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

Researchers are looking for new ways to treat metastatic cervical cancer. Cervical cancer is cancer in the cervix, the lower part of the uterus (womb). Metastatic means the cancer has spread to other parts of the body. Researchers want to …

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT07216703
Sites in Florida:
  • Florida Cancer Specialists - South ( Site 7001) — Fort Myers, Florida
  • Mount Sinai Braman Comprehensive Cancer Center ( Site 5043) — Miami Beach, Florida
  • Mount Sinai Comprehensive Cancer Center ( Site 6000) — Miami Beach, Florida
  • Florida Cancer Specialists - East ( Site 7000) — West Palm Beach, Florida
Phase 3 Recruiting Industry

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

The purpose of this study is to compare the efficacy and safety of ficlatuzumab plus cetuximab compared to placebo plus cetuximab in participants with recurrent/metastatic (R/M) HPV-negative Head and Neck Cancer. The primary hypothesis is …

Sponsor: AVEO Pharmaceuticals, Inc.
NCT ID: NCT06064877
Sites in Florida:
  • AdventHealth Medical Group Oncology & Hematology at Orlando — Orlando, Florida
  • Moffitt Cancer Center — Tampa, Florida
Phase 3 Recruiting Network

SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer

This study is being done to answer the following question: Is the chance of cancer spreading or returning the same if radiotherapy to the neck is guided, by using a special imaging study called lymph node mapping (lymphatic mapping) Single…

Sponsor: Canadian Cancer Trials Group
NCT ID: NCT05451004
Sites in Florida:
  • UM Sylvester Comprehensive Cancer Center at Coral Gables — Coral Gables, Florida
  • Baptist MD Anderson Cancer Center — Jacksonville, Florida
  • University of Miami Miller School of Medicine-Sylvester Cancer Center — Miami, Florida
  • Moffitt Cancer Center-International Plaza — Tampa, Florida
  • Moffitt Cancer Center - McKinley Campus — Tampa, Florida
Phase 2 Recruiting NIH

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

This phase II trial studies the good and bad effects of the combination of drugs called cabozantinib and nivolumab in treating patients with melanoma or squamous cell head and neck cancer that may have spread from where it first started to…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05136196
Sites in Florida:
  • Mayo Clinic in Florida — Jacksonville, Florida
Phase 1, Phase 2 Recruiting Industry

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) o…

Sponsor: Genmab
NCT ID: NCT05579366
Sites in Florida:
  • USOR Florida Cancer Specialists South — Fort Myers, Florida
  • USOR Florida Cancer Specialists North — St. Petersburg, Florida
  • USOR Florida Cancer Specialists East — West Palm Beach, Florida
Phase 1, Phase 2 Recruiting Industry

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the recommended Phase II dose (RP2D) of MCLA-158 single agent in patients with mCRC. The dose escalation part has been com…

Sponsor: Merus B.V.
NCT ID: NCT03526835
Sites in Florida:
  • Florida Cancer Specialists — Fort Myers, Florida
  • University of Florida — Gainesville, Florida
  • Sarah Cannon Research Institute (Lake Nona) — Orlando, Florida
Phase 1, Phase 2 Recruiting Industry

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311/BNT324 in subjects with advanced solid tumors.

Sponsor: DualityBio Inc.
NCT ID: NCT05914116
Sites in Florida:
  • Research Site 118 — Celebration, Florida
  • Research Site 127 — Margate, Florida
  • Research Site 137 — Orlando, Florida
  • Research Site 101 — Plantation, Florida
  • Research Site 109 — Tamarac, Florida
Phase 1, Phase 2 Recruiting Industry

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

Study STX-478-101 (LY4064809) is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 (LY4064809) in participants with advanced solid tumors with…

Sponsor: Eli Lilly and Company
NCT ID: NCT05768139
Sites in Florida:
  • Florida Cancer Specialists ORLANDO/DDU — Lake Mary, Florida
  • Moffitt Cancer Center — Tampa, Florida
Phase 1, Phase 2 Recruiting Industry

AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)

This study, the first clinical trial of AVZO-1418, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of AVZO-1418 when administered intravenously as a monotherapy…

Sponsor: Avenzo Therapeutics, Inc.
NCT ID: NCT07038343
Sites in Florida:
  • Avenzo Therapeutics Recruiting Site — Orlando, Florida
  • Avenzo Therapeutics Recruiting Site — Sarasota, Florida
  • Avenzo Therapeutics Recruiting Site — Tampa, Florida
Phase 2 Recruiting Industry

A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

This study is researching an experimental drug called fianlimab (also called REGN3767), combined with a medication called cemiplimab compared against cemiplimab combined with placebo (a placebo looks like a treatment but does not contain a…

Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT06769698
Sites in Florida:
  • Orlando Health — Orlando, Florida
Phase 2 Recruiting Industry

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ …

Sponsor: Jazz Pharmaceuticals
NCT ID: NCT06695845
Sites in Florida:
  • Florida Cancer Specialists - South — Fort Myers, Florida
  • Florida Cancer Specialists - Lake Nona — Orlando, Florida
  • Florida Cancer Specialists - North — St. Petersburg, Florida
  • Florida Cancer Specialists - East — West Palm Beach, Florida
Phase 1, Phase 2 Recruiting Industry

Lead-212 PSV359 Therapy for Patients With Solid Tumors

Phase I/IIa image-guided, alpha-particle therapy study of \[203Pb\]Pb-PSV359 and \[212Pb\]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.

Sponsor: Perspective Therapeutics
NCT ID: NCT06710756
Sites in Florida:
  • University of Miami — Miami, Florida
  • Biogenix — Miami, Florida
Phase 1, Phase 2 Recruiting Industry

A Study of DB-1310 in Advanced/Metastatic Solid Tumors

This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1310 in subjects with advanced solid tumors.

Sponsor: DualityBio Inc.
NCT ID: NCT05785741
Sites in Florida:
  • Research Site 117 — Coral Gables, Florida
  • D&H Cancer Research Center LLC — Margate, Florida
  • Sarah Cannon Research Institute at Florida Cancer Specialists — Orlando, Florida
  • BRCR global — Plantation, Florida
  • Florida Cancer Specialists — Sarasota, Florida
Phase 1, Phase 2 Recruiting Industry

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to avai…

Sponsor: VM Oncology, LLC
NCT ID: NCT03556228
Sites in Florida:
  • Holy Cross Hospital (site 213) — Fort Lauderdale, Florida
  • Memorial Cancer Institute at Memorial Healthcare Systems (site 132) — Pembroke Pines, Florida
Phase 2 Recruiting Industry

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma \[cutaneous/acral\], squamous cell carc…

Sponsor: Daiichi Sankyo
NCT ID: NCT06172478
Sites in Florida:
  • AdventHealth Medical Group Oncology Research at Celebration — Kissimmee, Florida
Phase 1, Phase 2 Recruiting Industry

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent and in combination with chemotherapy administered intravenously in participants with adva…

Sponsor: Marengo Therapeutics, Inc.
NCT ID: NCT05592626
Sites in Florida:
  • AdventHealth Celebration — Celebration, Florida
  • University of Miami Sylvester Comprehensive Cancer Center — Miami, Florida
Phase 2 Recruiting Industry

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

Researchers are looking for a better way to treat people who have solid tumors with HER2-activating mutations. Before a treatment can be approved for people to take, researchers do clinical trials to better understand its safety and how it…

Sponsor: Bayer
NCT ID: NCT06760819
Sites in Florida:
  • Florida Cancer Specialists & Research Institute - Fort Myers Cancer Center - Gladiolus — Fort Myers, Florida
Phase 1, Phase 2 Recruiting Industry

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

The goal of this study is to test A2B395, an allogeneic logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC)…

Sponsor: A2 Biotherapeutics Inc.
NCT ID: NCT06682793
Sites in Florida:
  • Mayo Clinic — Jacksonville, Florida
  • Moffitt Cancer Center — Tampa, Florida
Phase 2 Recruiting Industry

A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States

The purpose of this study is to characterize the clinical effects of tislelizumab, including pharmacokinetics (PK), activity, and safety assessments in US racial and ethnic minority patients with human epidermal growth factor receptor 2 (H…

Sponsor: BeOne Medicines
NCT ID: NCT07554521
Sites in Florida:
  • Brcr Coral Springs — Coral Springs, Florida
  • Bioresearch Partners Holding Hialeah Hospital — Hialeah, Florida
  • Florida Clinical Trials Group Plantation — Plantation, Florida
  • Florida Clinical Trials Group Tamarac — Tamarac, Florida
Phase 1, Phase 2 Recruiting Industry

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 alone for the treatment of patients with radiographically-confirmed progression of…

Sponsor: Neonc Technologies, Inc.
NCT ID: NCT06047379
Sites in Florida:
  • MDR Core Network — Boynton Beach, Florida

Showing 25 of 60 trials with sites in Florida. See all cervical cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-10-19